Related Experiment Video
Updated: Jun 11, 2025

Heterotopic Auxiliary Whole Liver Rat Transplant Model Utilizing a Hepaticoureterostomy for Allograft Rejection Studies
Published on: March 8, 2024
Simultaneous or sequential kidney-liver transplantation in primary hyperoxaluria
Maria Arena1, Raffaella Labbadia2, Andrea Cappoli2
1Nephrology Unit, Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. maria.arena@policlinicogemelli.it.
Background:
Primary hyperoxaluria type 1 is responsible for pediatric kidney failure in 1 to 2% of cases. Novel therapies based on RNA interference are changing the natural history of the disease. However, for those who do progress to kidney failure, and for patients living in countries that cannot afford these expensive therapies, liver-kidney transplantation may remain the only efficient therapy.
Methods:
The aim of the study was to evaluate the outcome of patients with primary hyperoxaluria type 1 who received simultaneous or sequential liver-kidney transplantation. We retrospectively evaluated 10 patients, five of whom received a simultaneous transplantation, and five underwent sequential transplantation, with a median postponement of the kidney transplantation of 8 months (range 4-20). Among the patients, 5 were from medium-low income countries.
Results:
Median follow up was 3.2 years (range 1.6-11). Median estimated glomerular filtration rate at 6 and 12 months was 81.2 (range: 45.7-108.8) and 79.3 ml/min/1.73m2 (range 54.7-112.1) in patients who underwent simultaneous transplantation, and 45.7 (range 34.5-86.7) and 38.3 ml/min/1.73m2 (range 29.9-77.5) in those with sequential transplantation (p:NS). Biopsies performed at 6 and 12 months showed precipitation of calcium oxalate crystals in 7 patients, demonstrating the recurrence of deposition despite the delay between liver and kidney transplantation. No differences in kidney function or in post-transplant renal oxalate precipitation were observed between patients that underwent bilateral nephrectomy and those who did not. As of their most recent follow up, none of the patients has lost their kidney graft.
Conclusions:
Our study shows that by adapting the transplant strategy to individual cases, patients with primary hyperoxaluria type 1 can be successfully treated.
Insights
Liver-kidney transplantation offers a successful treatment for primary hyperoxaluria type 1, even with oxalate crystal recurrence. Adapting transplant strategies ensures positive outcomes for patients with this rare kidney disease.
Area of Science:
- Nephrology
- Transplantation Immunology
- Genetics
Background:
- Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder leading to kidney failure in 1-2% of pediatric cases.
- While novel RNA interference therapies exist, liver-kidney transplantation remains a crucial option for advanced PH1, especially in resource-limited settings.
Purpose of the Study:
- To evaluate the outcomes of simultaneous versus sequential liver-kidney transplantation in patients with PH1.
- To assess the impact of transplant strategy on kidney function and oxalate crystal recurrence.
Main Methods:
- Retrospective analysis of 10 PH1 patients undergoing either simultaneous (n=5) or sequential (n=5) liver-kidney transplantation.
- Median follow-up of 3.2 years; kidney function assessed by eGFR; oxalate deposition evaluated via biopsies.
Main Results:
- No significant difference in kidney function (eGFR) between simultaneous and sequential transplant groups at 6 and 12 months.
- Oxalate crystal precipitation recurred in 7 patients, irrespective of transplant timing or bilateral nephrectomy.
- All patients retained their kidney grafts at the most recent follow-up.
Conclusions:
- Liver-kidney transplantation is an effective treatment for PH1, with successful graft survival observed.
- Tailoring the transplant approach to individual patient needs is key to successful management of PH1.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Kidney Transplant I: Introduction
Kidney Transplant III: Nursing Management

